Two Firsts For US Hand Sanitizer Firm: False COVID-19 Claims, Revamped Monograph Violation
Executive Summary
Less than a month after Congress passed legislation to comprehensively overhaul the FDA's OTC monograph program, the agency's warning to Prefense explains that its product formulation is noncompliant under amendments to the program.
You may also be interested in...
US Consumer Health 2020 News: ’60 Minutes’ Probiotic Dip Tops Switches, Monograph, Pandemic
Supplement industry’s bullseye on “60 Minutes” after its June segment critical of probiotic health benefits generated the most reads for a US consumer health and overall for HBW Insight articles in 2020. Articles about COVID-19 enforcement actions weren’t as widely read as coverage of FDA’s reorganization in its OTC drug offices and its approvals of additional ingredients to be available OTC.
FDA’s OTC Program Has Changed, But Antiseptic Sector Prepares For More Of The Same
The future of OTC antiseptic products – including antibacterial soaps and sanitizing hand rubs and wipes – came into serious question under FDA monograph actions taken in recent years. Stakeholders agree that Congress’s recently enacted CARES Act promises to transform OTC drug review, but the data requirements and uncertainty surrounding OTC germ-killing ingredients may be quickly reinstated.
US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry
With much of FDA's work currently focused on the COVID-19 pandemic, the agency has limited resources available to implement monograph changes authorized by recent legislation. Drug firms awaited a monograph overhaul with expectations for success where they previously failed, but they need FDA's guidance to succeed.